Patents Examined by Mark V Stevens
  • Mineral-based nanoparticles for arthritis treatment
    Patent number: 10898445
    Abstract: Aspects of the invention are directed to mineral-based nanoparticles comprising silicate nanoparticles that induce human mesenchymal stem cells (hMSCs) into a cartilage-lineage through the upregulation of cartilage-specific genes resulting in the transformation of the cell phenotype into that of a chondrocyte, i.e., a cartilage producing cell. The silicate nanoparticles are synthesized through a process where the precipitate of sodium silicate is mixed with one or more elements and compounds and milled into nanoparticles.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: January 26, 2021
    Assignee: The Texas A&M University System
    Inventors: Akhilesh K. Gaharwar, James K. Carrow
  • Finished pharmaceutical form with individual medicine dosing capability (embodiments) and methods of its production and use
    Patent number: 10898447
    Abstract: This invention relates to medical science and pharmaceutical technology. A new type of finished pharmaceutical form with individual medicine dosing capability is described comprising a storage container and a carrier on which the medicine is applied. Methods of production and use of the finished pharmaceutical form for individual medicine dosing are suggested.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: January 26, 2021
    Assignee: Psirrros Inc.
    Inventors: Sergey Emilevich Kondakov, Aleksandr Pavlovich Osipov, Mikhail Yakovlevich Melnikov, Dmitry Mikhailovich Mikhailov, Maxim Yurievich Mitrohin, Sergey Olegovich Belezkii, Vladimir Vladimirovich Gordeev
  • Immediate release abuse-deterrent granulated dosage forms
    Patent number: 10888528
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: January 12, 2021
    Assignee: Clexio Biosciences Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
  • Methods and dose packs for monitoring medication adherence
    Patent number: 10890591
    Abstract: Provided herein are methods and dose packs for the monitoring of medication adherence. In one aspect, the dose pack comprises comprise a multiplicity of doses of an agent and a multiplicity of doses of a marker and be configured to isolate a pair of at least one of the multiplicity of doses of the agent and at least one of the multiplicity of doses of the marker for co-administration of the pair to the subject according to the dosing schedule. In another aspect, the method comprises obtaining a sample from the subject subsequent to the conclusion of a monitoring window and analyzing the sample for the presence or absence of a marker or a degradation product thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: January 12, 2021
    Assignee: Synapse Biosciences, LLC
    Inventors: Robert Anthony Millet, Jr., Philip T. Radford, Ashwin Anand Patkar
  • Eye health composition
    Patent number: 10881638
    Abstract: Ophthalmic nutraceutical composition comprising: vitamins; trace elements; carotenoids; omega-3 fatty acids; and resveratrol.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 5, 2021
    Assignee: LABORATOIRES THEA
    Inventors: Céline Olmiere, Fabrice Mercier
  • Magnetically immobilized microbiocidal enzymes
    Patent number: 10881102
    Abstract: The present invention provides compositions and methods for reducing microbial contamination or infection in plants, animals, fabrics, and products therefrom. The present invention also provides compositions and methods for reducing human infections. In particular, it provides solid magnetic nanoparticles comprising bacteriostatic, bactericidal, fungistatic, or fungicidal enzymes in one component, and substrates for the enzymes in another component. The compositions are dormant and become active upon exposure to hydration and oxygen.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: January 5, 2021
    Assignee: ZYMtronix, LLC
    Inventor: Stephane Corgie
  • Cosmetic compositions
    Patent number: 10881699
    Abstract: A method of reducing the appearance of hyperpigmented skin or inflamed skin is disclosed. The method can include topically applying to hyperpigmented skin or inflamed skin a composition comprising an effective amount of an extract of Rhododendron ferrugineum leaf to reduce melanocyte pigmentation in the skin or to reduce tumor necrosis factor alpha (TNF-?) and cyclooxygenase-1 and -2 (COX-1 and COX-2) activity in the skin.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: January 5, 2021
    Assignee: Mary Kay Inc.
    Inventor: David Gan
  • Oral lipid supplements for treating pain and fibromyalgia
    Patent number: 10874681
    Abstract: A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating systemic pain from fibromyalgia. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: December 29, 2020
    Assignee: NUTRITIONAL THERAPEUTICS, INC.
    Inventor: Robert A. Settineri
  • Method for treating subjects suffering from chronic ulcers
    Patent number: 10869949
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 22, 2020
    Assignees: Geistlich Pharma AG, University of Southern California
    Inventors: Charles Zelen, David Armstrong, Paul Glat, Jarrod Kaufman, Marco Mehr, Lothar Schloesser, Mark Spilker
  • Non-aerosol shaving compositions
    Patent number: 10864149
    Abstract: The present invention relates to non-aerosol shaving compositions which are free of propellants, and methods of preparing and using such shaving composition. In particular, the present invention relates to a non-aerosol, propellant-free composition comprising: (i) at least two C14 to C16 carboxylic acids or an alkali metal salt thereof; (ii) at least one compound of general Formula (I) R—O—[—CH2CH2O—]n—CH2CO2H??(I) or an alkali metal salt thereof, wherein R represents a saturated, straight- or branched-chain C10 to C18 alkyl group; and n represents an integer between 4 and 12; (iii) polyvinyl pyrrolidone; and (iv) water.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: December 15, 2020
    Assignee: EDGEWELL PERSONAL CARE BRANDS, LLC
    Inventor: Peter Galow
  • Use of nitrite salts in chronic ischemia
    Patent number: 10864229
    Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 15, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventors: Christopher Kevil, David Lefer, Rakesh Patel
  • Process for the preparation and stabilization of emulsions with Omega-3 by means of isometric crystalline networks of cellulose derivatives
    Patent number: 10856564
    Abstract: The present invention relates to a novel emulsion structured in an isometric crystalline network of cellulose derivatives where the emulsion comprises Omega-3 fatty acids homogeneously distributed in the same. The emulsion of the invention has been designed to have greater stability, bioavailability and gastro-resistance and may be used in special medical foods, nutritional supplements, sports nutrition, enteral nutrition or child nutrition, amongst others.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: December 8, 2020
    Assignee: Solutex NA, LCC
    Inventors: Fernando Moreno Egea, Antonio Martínez Férez
  • Hydrogel membrane for adhesion prevention
    Patent number: 10850011
    Abstract: A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: December 1, 2020
    Assignee: Board of Regents, The University of Texas
    Inventors: Christine E. Schmidt, Scott A. Zawko, Sarah M. Mayes
  • Ophthalmic drug delivery
    Patent number: 10839960
    Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: November 17, 2020
    Assignee: Eyenovia, Inc.
    Inventors: Bernard L. Ballou, Jr., Mark Packer, Russell John Mumper, Tsontcho Ianchulev
  • Production of water-soluble hydrolyzed clinoptilolite fragments
    Patent number: 10828324
    Abstract: Methods are provided to make clinoptilolite into a water-soluble hydrolyzed form suitable for various administration routes, including oral administration. Absorption of water-soluble hydrolyzed clinoptilolite fragments can aid in detoxification by binding heavy metals and environmental toxins, can reduce reactive oxygen species and inflammation related to heavy metals and other/environmental toxins, resulting in an increase in energy, and/or in an increase in one or more of focus, concentration, and memory. Water-soluble hydrolyzed clinoptilolite fragments can be combined with one or more dietary supplements, including various vitamins and sleep aids.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 10, 2020
    Inventor: Nikolaos Tsirikos-Karapanos
  • Autostainer hematoxylin and methods of use
    Patent number: 10830675
    Abstract: This disclosure relates to hematoxylin staining formulations and particularly to formulations for use in autostainers. The disclosed compositions were discovered to possess atypical stability under storage while having high stain quality and sufficiently fast staining performance. The disclosed hematoxylin staining compositions include a solvent system, hematoxylin, a chemical oxidant, and a mordant. Illustrative embodiments also have a Cl?/SO4? molar ratio of between about 2.5/1 and about 1/4.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: November 10, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Heidi Barnett, Edward E. Durrant, Eric L. Klein, Michael Lynch, Kevin H. Pritchard
  • Labeled chemically reactive and biologically active conjugates, and methods and compositions thereof
    Patent number: 10815248
    Abstract: The invention generally relates to novel fluorophore-labeled, bi- or multi-functional, chemically reactive and/or biologically active conjugates, and related compositions and methods thereof.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: October 27, 2020
    Inventor: Yi Sun
  • Use of aerosolized levofloxacin for treating cystic fibrosis
    Patent number: 10792289
    Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 6, 2020
    Assignee: Horizon Orphan LLC
    Inventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
  • Topical composition for reducing age spots and wrinkles
    Patent number: 10786442
    Abstract: A topical composition for treating age spots and wrinkles includes at least one first skin-whitening agent, at least one wrinkle-reducing agent, and a pharmaceutically or cosmetically acceptable solvent. In a preferred embodiment, the composition includes two whitening agents and two wrinkle-reducing agents. The skin-whitening agents include a tyrosinase-inhibiting glycosylated hydroquinone and a blend of alpine plant-based extracts. The wrinkle-reducing agents include avian egg extract and stabilized vitamin C.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: September 29, 2020
    Inventor: Wicky Suyanto
  • Treatment of disease with poly-N-acetylglucosamine nanofibers
    Patent number: 10765698
    Abstract: This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: September 8, 2020
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein